Telomere length is associated with disease severity and declines with age in dyskeratosis congenita

by Blanche P. Alter, Philip S. Rosenberg, Neelam Giri, Gabriela M. Baerlocher, Peter M. Lansdorp, and Sharon A. Savage

Haematologica 2011 [Epub ahead of print]

Citation: Alter BP, Rosenberg PS, Giri N, Baerlocher GM, Lansdorp PM, and Savage SA. Telomere length is associated with disease severity and declines with age in dyskeratosis congenita. Haematologica. 2011; 96:xxx

Publisher’s Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in print on a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.

Haematologica (pISSN: 0390-6078, eISSN: 1592-8721, NLM ID: 0417435, www.haematologica.org) publishes peer-reviewed papers across all areas of experimental and clinical hematology. The journal is owned by the Ferrata Storti Foundation, a non-profit organization, and serves the scientific community with strict adherence to the principles of open access publishing (www.doaj.org). In addition, the journal makes every paper published immediately available in PubMed Central (PMC), the US National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature.
Telomere length is associated with disease severity and declines with age in dyskeratosis congenita

Blanche P. Alter, Philip S. Rosenberg, Neelam Giri, Gabriela M. Baerlocher, Peter M. Lansdorp, and Sharon A. Savage

1Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA; 2Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD, USA; 3Hematology, University Hospital, Berne, Switzerland, and 4Terry Fox Laboratory, British Columbia Cancer Research Centre, Vancouver, BC, Canada

Correspondence

Blanche P. Alter, MD, MPH, National Cancer Institute, 6120 Executive Blvd, Executive Plaza South Room 7020, Rockville, MD, 20852-7231 USA. Phone: international +310.4029731. Fax: international +301.4961854. E-mail: alterb@mail.nih.gov

DOI: 10.3324/haematol.2011.055269
Abstract

**Background.** Dyskeratosis congenita is a cancer-prone bone marrow failure syndrome caused by aberrations in telomere biology.

**Design and Methods.** We studied 65 patients with dyskeratosis congenita and 127 unaffected relatives. Telomere length was measured by automated multicolor flow fluorescence *in situ* hybridization in peripheral blood leukocyte subsets. We age-adjusted telomere length using Z-scores (standard deviations from the mean for age).

**Results.** We confirmed that telomere lengths below the first percentile for age are very sensitive and specific for the diagnosis of dyskeratosis congenita. We provide evidence that lymphocytes alone and not granulocytes may suffice for clinical screening, while lymphocyte subsets may be required for challenging cases, including identification of silent carriers. We show for the first time using flow fluorescence *in situ* hybridization that the shortest telomeres are associated with severe variants (Hoyeraal-Hreidarsson and Revesz syndromes); mutations in *DKC1, TINF2*, or unknown genes; and moderate or severe aplastic anemia. In the first longitudinal follow-up of dyskeratosis congenita patients, we demonstrate telomere lengths decline with age, in contrast to the apparent stable telomere length observed in cross-sectional data.

**Conclusions.** Telomere length by flow fluorescence *in situ* hybridization is an important diagnostic test for dyskeratosis congenita; age-adjusted values provide a quantitative measure of disease severity (clinical subset, mutated gene, and degree of bone marrow failure). Patients with dyskeratosis congenita have accelerated telomere shortening.

Key words: bone marrow failure, dyskeratosis congenita, telomeres, longitudinal study.

**Trial registration:** This study is registered at www.clinicaltrials.gov (identifier: NCT00027274).
Introduction

Dyskeratosis congenita (DC, MIM 30500, 127550, 224230) is an inherited bone marrow failure syndrome in which abnormalities in telomere biology lead to very short telomeres (1). Telomeres are long nucleotide repeats (TTAGGG)n at the ends of chromosomes, which protect chromosomal integrity (2;3). More than half of the patients with DC have mutations identified in a gene required for telomere maintenance (DKC1, MIM 30126; TERC, MIM 602322; TERT 187270; TINF2, MIM 604319; NHP2, MIM 606470; NOP10, MIM 606471; or WRAP53 [protein TCAB1], MIM 612661); inheritance is X-linked recessive, autosomal dominant, or autosomal recessive. In addition to the diagnostic triad of nail dystrophy, lacey reticular pigmentation, and oral leukoplakia, patients with DC are at very high risk of bone marrow failure (BMF), cancer, pulmonary and liver disease, and multiple other medical problems (4;5). The diagnostic triad and other DC-related physical findings and complications frequently develop over time and at different rates, which can make the diagnosis challenging (6). Correct diagnosis is important for medical management, genetic counseling, and decisions regarding hematopoietic stem cell transplantation (HSCT). Identification of DC in apparently healthy family members who may be HSCT donors is especially important because stem cells from an individual with undiagnosed DC fail to rescue the DC patient’s bone marrow (7).

In our previous report of 26 patients with DC and 54 relatives, we showed that telomere length was diagnostic for DC. Specifically, we found that telomeres below the first percentile for age measured in peripheral blood leukocyte subsets using automated multicolor flow fluorescence in situ hybridization (flow FISH) clearly discriminated between patients with DC and unrelated normal controls or unaffected relatives (8).
We now have a much larger cohort, with more than double the numbers of participants, 65 patients and 127 relatives. The new data replicate our original results, and the combined cohort provides a more robust assessment of which blood cell types are most informative for clinical decision-making. Furthermore, the association between telomere length and genotype, phenotype, and clinical complications has not previously been adequately described, because the earlier studies by us and others lacked statistical power (8;9), although we and others did observe very short telomeres in several patients with mutations in TINF2 (10-12). In the current large study we show that baseline telomere length measured by automated multicolor flow FISH is highly associated with clinical DC subtypes, genotypes, and hematological status. In addition, prior studies using cross-sectional data suggested that telomere lengths in patients with DC were stable over time (8;9). We now present the first longitudinal data which provide clear evidence that telomeres shorten significantly more rapidly with age in patients with DC than in unaffected individuals.

**Design and Methods**

**Participants**

This study was approved by the Institutional Review Board of the National Cancer Institute, is a component of NCI protocol 02-C-0052, and is registered in www.clinicaltrials.gov (NCT00027274). The original cohort enrolled between January 2000 and July 2006 (8), while the new cohort enrolled from August 2006 through the end of December 2010. All analyses were done with the combined data.

Individuals with “classic DC” often had a component of BMF, and always had at least one feature of the diagnostic triad (dyskeratotic fingernails, lacy reticular pigmentation, and oral
leukoplakia) or other physical abnormalities (6). A silent carrier of DC was a clinically unaffected first degree relative who shared the proband’s germline mutation in a DC gene. Family members who had the familial mutation, with a history of BMF, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), or a DC-type cancer (primarily head and neck or anogenital squamous cell carcinoma) were included as “classic DC” (13). Severe subtypes of DC included Hoyeraal-Hreidarsson (HH) and Revesz syndromes (RS). HH is characterized by cerebellar hypoplasia, microcephaly, developmental delay, immunodeficiency, intrauterine growth retardation, and BMF; features defining RS are bilateral exudative retinopathy (similar to acquired unilateral Coats’ retinopathy), intrauterine growth retardation, BMF, sparse fine hair, and central nervous system (CNS) calcifications (5). Patients with an inherited BMF syndrome other than DC (14) were excluded. Probands with aplastic anemia and very short telomeres, but no physical features of DC, and wild-type DC genes, were also excluded, as were their relatives, despite the caveat that some of them may turn out to have DC once all DC genes have been identified.

To be conservative and avoid potential over-classification of DC, family members of bona fide DC patients, who had very short telomeres, lacked any physical abnormalities, were hematologically normal, and did not have a mutated DC gene were called “DC Relatives”, along with family members whose telomeres were within the normal range (8). “DC Rel 1” included members of families where the proband did not have a mutation in a known DC gene, while “DC Rel 2” was the classification for family members where the proband’s mutated gene was identified, but the relative lacked the familial mutation. Relatives were primarily parents and siblings, with a few grandparents included. The classification of “DC patient” versus “DC
relative” may change as new genes are found for DC, or if signs of DC develop in those individuals.

**Laboratory methods**

Gene sequencing was performed in CLIA-certified laboratories. Patients designated as “unknown genotype” were wild type for all known DC genes. Bone marrow status was classified as severe aplastic anemia (SAA) when Hb was <8 g/dl, neutrophils <500/µl, and platelets <20,000/µl (15); moderate aplastic anemia (MAA) when values were below normal but not SAA, and normal when values were within the normal range for age.

The method used for automated multicolor flow FISH measurement of telomere lengths was described previously (8;16). We analyzed six leukocyte subsets: granulocytes, total lymphocytes, CD45RA-positive/CD20-negative naïve T cells, CD45RA-negative memory T cells, CD20-positive B cells, and CD57-positive NK/NKT cells. Normal telomere lengths in kilobases (kb) were determined from ~400 normal individuals ranging from birth to 100 years of age. “Very short” telomeres were defined as below the first percentile of the age-matched controls. Denominators for analyses included only the number of patients for whom a given lineage was available.

**Statistical methods**

Since normal telomere length decreases with age, age-adjustment was provided by conversion of individual data into Z-scores using the formula: $Z\text{-score} = (X - \mu) / \sigma$, where $X =$ the telomere length for the patient, $\mu =$ the mean telomere length for age-matched controls, and $\sigma =$ the standard deviation (SD) of age-matched controls. The $Z$-score compared the telomere measurement in each individual with the age-matched mean and SD of the values in the normal controls, and thus accounted for the known wide inter-individual telomere length variability. Z-
scores are more precise than delta TEL, which compares telomere length in a case to the value in a single age-matched control or to the mean of such controls. The Z-score below the first percentile of a normal distribution (-2.33 SD) was considered diagnostic for DC in these analyses; a normal Z-score would be zero. Use of the Z-score permitted comparisons of telomere length between patients with DC and normal controls, and within diverse subtypes of patients with DC, as well as patients with DC with their relatives, with all comparisons adjusted for possible differences in age.

Analyses were performed with Microsoft Excel (Microsoft Office Excel 2007) and Stata11 (StataCorp Release 11.1, College Station, TX). P-values were two-sided; \( p<0.05 \) was considered statistically significant. Performance characteristics included odds ratios (OR) in favor of DC, 95% confidence intervals (CI), sensitivity (sens), specificity (spec), and positive and negative predictive values (PPV and NPV), based on the frequency of telomeres below the first percentile of normal in comparisons between patients with DC and their unaffected relatives.

**Results**

*Diagnostic utility of leukocyte subsets*

The total cohort (Table 1) consists of 65 patients with DC and 127 unaffected relatives (45 in families without known genes, and 82 in families in which the gene is known). Detailed information about the original dataset (26 patients and 54 relatives) was published previously (8). Twenty-four patients were members of nine families, while 41 were the only affected person in their family. Patients were significantly younger than their relatives, and twice as many patients were less than 18 years of age. There was an excess of males in the DC patients. Twelve males
had mutations in *DKC1*, and 17 in other DC genes; 18 males had unknown genotypes. Ten females had mutations identified, while eight were unknown. Overall, about one-fourth of the patients had mutations in *TINF2*, while 40% did not have mutations in any of the known genes. Unlike findings reported by another group in which the patients with *TINF2* mutations were predominantly children (11;12), our 15 patients with these mutations included eight children (0-13 years) and seven adults (21-70 years). The diagnostic triad was represented by at least two features in about half the DC patients. One-third of the DC patients had no marrow failure at the time of diagnosis; this includes the seven silent carriers as well as two patients with some non-triad DC physical findings.

The results for the telomere lengths are shown in Figure 1 for the six leukocyte subsets that were analyzed. In general, the telomeres from the DC patients were significantly shorter than the normal controls (below the first percentile of normals for age), and shorter than the DC relatives. There was some variation across leukocyte subsets. In particular, 22 relatives had very short telomeres in granulocytes compared with 11 or less in other lineages. The relatives with very short telomeres in multiple lineages may be silent carriers in families in which the DC gene is not yet known. Conversely, two DC patients (mutation positive) had telomeres that were clearly in the normal range in granulocytes but were very short in several other lineages.

We compared the numbers of DC patients with the number of unaffected relatives with very short telomeres (Table 2). Granulocytes were very sensitive but not very specific, leading to a low PPV (73%). In contrast, total lymphocytes had sensitivity and specificity of 97% and 91% respectively, and 85% PPV. The data suggest that total lymphocytes perform better than granulocytes to diagnose DC if only a single lineage is studied. Several combinations of lymphocyte subsets or individual lymphocyte lineages all had sensitivities and specificities
above 90%. Since CD57+ NK/NKT cells are a very heterogeneous group of cells, the telomere length of this category had a greater variability (SD was higher) and the yield and sensitivity were poor compared with other lymphocyte subsets. The best performance characteristics appear to be in the group in which three of the four lymphocyte subsets were very short, with sensitivity and specificity of 98% and 94%, and the highest PPV, 89%. This group had the highest odds ratio in favor of a DC patient versus a relative, 926, compared with 332 for total lymphocytes.

Misclassification was rare. Only two patients (silent carriers, with mutations in DC genes) would have been classified as normal using lymphocytes alone, or using three of four lymphocyte subsets. However, 11 relatives would be classified as DC using lymphocytes, compared with seven (36% fewer) using the three of four lymphocyte subsets strategy. The seven relatives with very short telomeres in the lymphocyte subsets were all included among the 11 with very short telomeres in total lymphocytes. These relatives were asymptomatic, and were primarily in families in which the mutated gene in the proband was unknown.

**Association of telomere length with disease severity**

Transformation into Z-scores was used to adjust for age, and permitted comparisons of several groups. As a combined group, telomere Z-scores in DC patients were well below the range of their relatives ($p<0.001$) (Figure 2A shows data for lymphocytes). Patients with the severe HH and RS phenotypes had much lower age-adjusted Z-scores than patients with classic DC or silent carriers ($p=0.001$ by rank sum). The HH and RS subtypes typically develop medical problems consistent with DC at very young ages, which could be a consequence of the exceedingly short telomeres in these patients. The relatives of patients in whom the mutated gene had not been identified (Rel 1) had lower telomere Z-scores than the unaffected relatives (Rel 2)
in whose family the gene was known; this could reflect inclusion of currently unidentified silent carriers.

There was a significant effect of genotype on lymphocyte telomere length Z-scores (Figure 2B). Patients with mutations in unknown genes, in \textit{TINF2} or in \textit{DKC1} had shorter telomeres than those with \textit{TERT, WRAP53}, or \textit{TERC} mutations (p = 0.01). The Z-scores for the first three categories listed were around minus 5 SD, while they were around minus 4 for the second set of three genes. Lower Z-scores were also associated with more severe BMF (Figure 2C). The patients with normal hematopoiesis had Z-scores of around minus 3.6 SD, while those with MAA or SAA had respective Z-scores of around minus 4.6 and minus 5.4 (p for trend = 0.001). There was also a trend towards lower Z-scores with more features of the diagnostic triad. Specifically the average Z-score was minus 4.6 for patients with none or only one feature of the triad, compared with minus 4.6 and minus 5.3 in those with two or three such features respectively (p=0.08) (Figure 2D). Results for leukocyte subsets other than lymphocytes showed similar associations (data not shown).

\textit{Telomeres shorten with age in patients with DC}

We evaluated longitudinal changes in telomere length in nine patients with DC with measurements repeated once at a median of 5.5 years (range 4.9-7.0) after the first measurement. Data for all leukocyte subsets are shown in Figure 3; details are provided here for lymphocytes. The slopes for lymphocytes in the patients with DC averaged minus 0.17 kb +/- 0.1 (range minus 0.02 to 0.34) per year; after exclusion of the three patients with \textit{TERC} mutations (NCI 6-1, NCI 6-2, and NCI 114-1), the slopes averaged minus 0.22 kb +/- 0.07. The normal slope (based on the cross-sectional decline in the normal controls shown in Figure 3) was minus 0.05-0.1 kb, \textit{i.e.} an annual loss of 0.05-0.1 kb, less than the value in the nine DC patients. The mean decline in Z-
score in the patients from the first to the second lymphocyte sample over the five years was significant, minus 0.5 SD (p = 0.02 by Wilcoxon signed rank test, and 0.01 by paired t test, data not shown). If the DC patients’ telomeres were tracking the normal age-associated decline, there should have been no change in the Z-score.

The dashed lines represent the summary linear trends in the cross-sectional data from the patients with DC and their relatives (Figure 3). Consistent with previous observations by us and by Du et al (8;9), the cross-sectional results from all DC patients were essentially flat (for lymphocytes, p = 0.4 by F-test compared with zero slope; for all leukocyte subsets p = 0.1 to 0.9). As expected, the cross-sectional telomere lengths from the DC relatives demonstrated a significant decline with age, similar to the cross-sectional control data (p <0.001 for all leukocyte subsets). The longitudinal measurements thus demonstrate a significant decline with age in individual DC patients, in contrast to the lack of decline observed in the cross-sectional analyses.

Discussion

DC is characterized by exceedingly short telomeres and mutations in telomere biology genes. In our first report, we found that very short telomeres in leukocyte subsets measured by automated multicolor flow FISH were diagnostic of DC. Our new data confirm that telomere length less than the 1st percentile for age in normals in leukocyte subsets is highly sensitive and specific for DC, and suggest that telomere length in patients with DC is a fundamental measure of clinical severity. The precision of the automated method provides highly reproducible results with a very low standard deviation.

Our study suggests that flow FISH telomere length in granulocytes is not a useful diagnostic tool, despite the accuracy of the measurements, because of the low specificity and PPV. Rather, the most useful single lineage screening test for DC is total lymphocytes, with a
PPV of 85%. We agree that relatives who do not carry mutations in DC genes have essentially normal lymphocyte telomere lengths (17). However, in cases in which the diagnosis is not clear, such as in a relative who may or may not be a silent carrier, the additional information gleaned from telomere length measurements in lymphocyte subsets (i.e. below the first percentile in three of the four subsets) may be critical. This is especially important in clinically normal relatives of a patient with an unknown gene mutation who are being considered as hematopoietic stem cell donors (7). Indeed in our cohort, one silent carrier has subsequently developed mild thrombocytopenia and a hypocellular marrow.

The size of our cohort, analysis by flow FISH, and age-adjustment with Z-scores permitted detailed comparisons of flow FISH telomere length in DC subgroups. We found that extremely short telomeres were strongly associated with the more severe clinical phenotypes, HH and RS, even though the gene associated with these phenotypes has not yet been discovered in many of these patients (five of our 15 with HH were due to \textit{DKC1} mutations, and one of the four with RS had a mutation in \textit{TINF2}). There was also a trend toward shorter telomeres in those patients with more features of the diagnostic triad. Ongoing longitudinal studies of the clinical complications in these patients are required to better understand these associations.

Patients with mutations in \textit{DKC1}, \textit{TINF2}, and unknown genes had shorter telomeres than those with mutations in \textit{TERC}, \textit{TERT}, and \textit{WRAP53}. The former group was younger than the latter, but the use of Z-scores permitted us to conclude for the first time that the association of telomere length with genotype was independent of age. Walne \textit{et al} also found that telomeres were shortest in patients with mutations in \textit{TINF2}, followed by \textit{DKC1}, compared with controls, using Southern blots and delta Tel, rather than flow FISH (11). These findings suggest that
sequencing of TINF2 and DKC1 (the latter in males) should precede examination of the other known DC genes in patients with extremely short telomeres.

Patients with more severe hematologic disease (SAA or MAA) had significantly shorter telomeres than patients without AA. This may reflect that in patients with the shortest telomeres in peripheral blood cells, telomeres in the hematopoietic stem cells are too short to support adequate differentiation. Alternatively, this could be related to the severity of bone marrow stress, with subsequent accelerated shortening of telomeres.

Our longitudinal study of nine patients with DC shows that not only does telomere length decline with age, but that the decline may be accelerated when compared with the predicted normal rate (approximately 0.2 kb per year compared with 0.05) (18). This is in contrast with the flat cross-sectional results, which may be due to a “survival bias” reflecting that older patients in the cohort had to survive complications of DC and hence tended to be those with a milder phenotype (8;9). Younger patients with a more severe phenotype may be identified as DC by their clinical presentation, while older patients whose course is milder may be recognized only after they develop age-associated complications.

Our cohort has several strengths, which include detailed characterization of the physical and laboratory features of children and adults, using identical criteria, as well as personal examination of the majority of the participants. Automated flow FISH of leukocyte subsets is precise, reproducible, sensitive and specific. The limitations of our study include the fact that family members may currently be misclassified as “unaffected relatives”, and may later be reclassified as “silent carriers” only when mutated DC genes are identified in their families. Many DC-associated clinical and laboratory findings are age-dependent. The NCI cohort may be subject to biased referrals or volunteerism of unknown magnitudes. Our dataset is not
sufficiently large to determine whether some of the interesting associations we noted are independent or correlated, such as DC subtype, age, features of the triad, genes, and BMF. In addition, we do not have longitudinal measurements of telomere length from relatives, patients with acquired aplastic anemia, or normal controls.

Taken together, our new data suggest that, when telomere lengths in patients with DC are measured precisely and age is accounted for, the values provide a fundamental measure of disease severity. Furthermore, our results also stress the potential clinical importance of obtaining longitudinal data to determine the rate of telomere loss in individuals with DC. It is possible that patients with excessive telomere attrition rates (e.g., > 0.2 kb/year) may be on a more rapid trajectory towards a serious complication of this disorder. Understanding the interplay of all the features discussed above require longer follow-up of a larger cohort. These findings will aid in the identification of patients who are most likely to have DC, and who thus require syndrome-specific management and medical and genetic counseling.

Acknowledgments

The authors would like to thank all the subjects for their enthusiastic participation in the IBMFS study. We also thank Mark H Greene, MD, for helpful discussions; Irma Vulto for excellent technical assistance; and Lisa Leathwood RN, and members of the IBMFS team at Westat for their extensive efforts.
Funding

This research was supported in part by the Intramural Research Program of the National Institutes of Health and the National Cancer Institute (BPA, NG, SAS, PSR.), and by contracts N02-CP-91026, N02-CP-11019 and HHSN261200655001C with Westat, Incorporated. GMB was supported by the Swiss National Foundation and the Bernese Cancer League. Work in the Lansdorp laboratory was supported by grants from the Canadian Institutes of Health Research (RMF-92093), the NIH (R01GM094146), the Canadian Cancer Society and the Terry Fox Foundation (018006 and 105265).

Authorship and Disclosures

All authors participated in designing and analyzing the research; SAS performed analyses of DC genes; NG provided clinical support to all patients in the study. BPA, SAS, and PSR wrote the paper, and all authors revised the paper and checked the final version of the manuscript. PML is a founding shareholder in Repeat Diagnostics Inc., a company specializing in leukocyte telomere length measurements using flow FISH. GMB receives grant support from Geron Corporation.
References


Table 1. Subjects in cohort.

<table>
<thead>
<tr>
<th></th>
<th>DC</th>
<th>HH</th>
<th>RS</th>
<th>Silent</th>
<th>All DC</th>
<th>DC Rel 1</th>
<th>DC Rel 2</th>
<th>All DC Relatives</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>40</td>
<td>14</td>
<td>4</td>
<td>7</td>
<td>65</td>
<td>45</td>
<td>82</td>
<td>127</td>
</tr>
<tr>
<td>Age median (range)</td>
<td>17 (2-47)</td>
<td>2 (1-18)</td>
<td>4.5 (1-13)</td>
<td>26 (0-70)</td>
<td>14 (0-70)²</td>
<td>29 (0.2-64)</td>
<td>41 (0-87)</td>
<td>34 (0-87)</td>
</tr>
<tr>
<td>No. &lt;18 yr</td>
<td>21</td>
<td>13</td>
<td>4</td>
<td>3</td>
<td>41 (69%)</td>
<td>16 (36%)</td>
<td>14 (17%)</td>
<td>30 (24%)</td>
</tr>
<tr>
<td>DC triad, no.</td>
<td>25</td>
<td>8</td>
<td>1</td>
<td>0</td>
<td>34 (52%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Mutations³</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DKC1</td>
<td>6:0</td>
<td>5:0</td>
<td>0</td>
<td>1:0</td>
<td>12:0 (18%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>TINF2</td>
<td>7:3</td>
<td>0</td>
<td>1:0</td>
<td>2:2</td>
<td>10:5 (23%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>TERC</td>
<td>0:4</td>
<td>0</td>
<td>0</td>
<td>1:0</td>
<td>1:4 (8%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>TERT</td>
<td>4:0</td>
<td>0</td>
<td>0</td>
<td>0:1</td>
<td>4:1 (8%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>WRAP53</td>
<td>2:0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>2:0 (3%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Unknown</td>
<td>9:5</td>
<td>7:2</td>
<td>2:1</td>
<td>0</td>
<td>18:8 (40%)</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>BMF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>None</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>7</td>
<td>9 (18%)</td>
<td>45</td>
<td>82</td>
<td>127</td>
</tr>
<tr>
<td>Moderate</td>
<td>11</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>18 (25%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Severe</td>
<td>25</td>
<td>8</td>
<td>4</td>
<td>0</td>
<td>38 (57%)</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

Age in years is at the time of the telomere assay. Triad, number of individuals with two or three features. BMF, bone marrow failure. Severe BMF includes 29 patients on transfusions or androgen therapy. DC, dyskeratosis congenita. HH, Hoyeraal-Hreidarsson. RS, Revesz syndrome. Silent, silent carriers, proven by mutation, with no physical or hematologic signs. DC Rel 1, DC relatives in families in which the mutated gene has not been identified in the proband. DC Rel 2, DC relatives with normal genes in families in which the mutated gene has been identified in the proband. NA, not applicable. There were no patients with mutations in NHP2 or NOP10. ¹Excess of males, p <0.001. ²DC patients younger than DC relatives, p <0.001. ³Mutated genes are enumerated as found in males:females; % is for the total frequency of the gene. ⁴Excess of females, p=0.04.
Table 2. Telomere lengths in DC patients compared with DC relatives.

<table>
<thead>
<tr>
<th>Cell Type</th>
<th>DC Patients</th>
<th>DC Relatives</th>
<th>OR</th>
<th>95% CI</th>
<th>Sens (%)</th>
<th>Spec (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Granulocytes</td>
<td>60/62</td>
<td>22/123</td>
<td>138</td>
<td>31-1200</td>
<td>97</td>
<td>82</td>
<td>73</td>
<td>98</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>63/65</td>
<td>11/127</td>
<td>332</td>
<td>68-2942</td>
<td>97</td>
<td>91</td>
<td>85</td>
<td>98</td>
</tr>
<tr>
<td>CD45RA+/CD20- naïve T cells</td>
<td>61/64</td>
<td>9/127</td>
<td>266</td>
<td>64-1468</td>
<td>95</td>
<td>93</td>
<td>87</td>
<td>98</td>
</tr>
<tr>
<td>CD45- memory T cells</td>
<td>61/64</td>
<td>11/127</td>
<td>214</td>
<td>53-1161</td>
<td>95</td>
<td>91</td>
<td>85</td>
<td>98</td>
</tr>
<tr>
<td>CD20+ B cells</td>
<td>54/58</td>
<td>12/127</td>
<td>129</td>
<td>37-546</td>
<td>93</td>
<td>91</td>
<td>82</td>
<td>97</td>
</tr>
<tr>
<td>CD57+ NK/NKT cells</td>
<td>50/59</td>
<td>12/119</td>
<td>50</td>
<td>18-140</td>
<td>85</td>
<td>90</td>
<td>81</td>
<td>92</td>
</tr>
<tr>
<td>&gt;4/6 lineages</td>
<td>61/64</td>
<td>9/117</td>
<td>244</td>
<td>58-1346</td>
<td>95</td>
<td>92</td>
<td>87</td>
<td>97</td>
</tr>
<tr>
<td>&gt;3/5 lymphocyte lineages</td>
<td>62/64</td>
<td>9/119</td>
<td>379</td>
<td>74-3390</td>
<td>97</td>
<td>92</td>
<td>87</td>
<td>98</td>
</tr>
<tr>
<td>4/4 lymphocyte subsets</td>
<td>42/55</td>
<td>7/127</td>
<td>55</td>
<td>19-170</td>
<td>76</td>
<td>94</td>
<td>86</td>
<td>90</td>
</tr>
<tr>
<td>&gt;3/4 lymphocyte subsets</td>
<td>54/55</td>
<td>7/127</td>
<td>926</td>
<td>113-37479</td>
<td>98</td>
<td>94</td>
<td>89</td>
<td>99</td>
</tr>
<tr>
<td>3/3 naïve and memory T and B cells</td>
<td>51/58</td>
<td>7/127</td>
<td>125</td>
<td>38-437</td>
<td>88</td>
<td>94</td>
<td>88</td>
<td>94</td>
</tr>
<tr>
<td>&gt;2/3 naïve and memory T and B cells</td>
<td>57/58</td>
<td>9/127</td>
<td>747</td>
<td>97-30241</td>
<td>98</td>
<td>93</td>
<td>86</td>
<td>99</td>
</tr>
<tr>
<td>2/2 naïve and memory T cells</td>
<td>59/64</td>
<td>7/127</td>
<td>202</td>
<td>55-806</td>
<td>92</td>
<td>94</td>
<td>89</td>
<td>96</td>
</tr>
<tr>
<td>1/2 naïve and memory T cells</td>
<td>63/64</td>
<td>13/127</td>
<td>552</td>
<td>77-22333</td>
<td>98</td>
<td>89</td>
<td>83</td>
<td>99</td>
</tr>
<tr>
<td>Granulocytes + Lymphocytes</td>
<td>58/65</td>
<td>11/127</td>
<td>87</td>
<td>30-273</td>
<td>89</td>
<td>91</td>
<td>84</td>
<td>94</td>
</tr>
</tbody>
</table>

Denominators vary according to the number of patients in whom each included lineage had sufficient numbers of cells for analysis. The best performance characteristics are in lymphocytes alone, and at least three of the four lymphocyte subsets. Abnormal, below the first percentile for age in normals. OR, odds ratio in favor of being a DC patient compared with an unaffected relative. CI, confidence interval. Sens, sensitivity. Spec, Specificity. PPV, positive predictive value. NPV, negative predictive value.
Figure Legends

Figure 1. Telomere length according to age in patients with DC and their relatives. The vertical axis represents telomere length in kb. The curved lines in the figures indicate the 1st, 10th, 50th, 90th, and 99th percentiles of results from 400 normal controls. Colored symbols represent patients with DC and their relatives. Red circles, classical DC patients. Green triangles, Hoyeraal-Hreidarsson. Teal blue diamonds, Revesz syndrome. Blue squares, silent carriers. Open black squares, DC relatives in families with unknown genes. Open black triangles, DC relatives without mutations in the probands’ genes. Top panels show granulocytes, lymphocytes, and CD45RA-positive/CD20-negative naïve T-cells. Bottom panels show CD45RA-negative memory T-cells, CD20-positive B-cells, and total leukocytes.

Figure 2. Telomere length Z-scores in DC patients according to various categories, and relatives. A) Typical DC patients, silent carriers with mutations in DC genes, Hoyeraal-Hreidarsson (HH), and Revesz Syndrome RS). Telomeres for those with HH and RS are much shorter than in other DC patients and silent carriers after age-adjustment by Z-scores; p=0.002 by rank sum. All DC patients have lower Z-scores when compared with relatives, p<0.0001 by Student t test. Outliers among relatives with low Z-scores may include silent carriers of DC in families in which genes have not been identified. Telomere Z-scores in relatives in families without known genes are lower than in those in families with known mutations, p=0.02 by Student t test. B) Telomere Z-scores are lower in those with mutations in unknown genes, DKC1, and TINF2 than in those with mutations in TERC, TERT, and WRAP53; p=0.01 by rank sum. C) The Z-scores are lower in those with increased severity of bone marrow failure (MAA=moderate aplastic anemia, SAA=severe aplastic anemia); p for trend=0.001. Z-scores in patients without aplastic anemia are similar to those with MAA, p=0.1; SAA are lower than MAA, p=0.05; and SAA are much lower than those with no AA, p<0.001. D) Telomere Z-scores are not significantly different in those with two or three features of the clinical triad than in those with none or only one such features; p = 0.08.

Figure 3. Regression lines for telomere length according to age. The short lines indicate the change in telomere lengths in nine DC patients over five year intervals. Red, NCI-6-1 and NCI-6-2 are mother and son with a mutation in TERC. Blue, NCI-26-1 and NCI-26-2 are identical twins with a mutation in TERT. Teal blue, NCI-74-3 and NCI-74-5 are brothers with a mutation in TINF2. Green, NCI-106-1 and NCI-106-3 are brothers with mutation in DKC1. Black, NCI-114-1 with a mutation in TERC. The slope of the cross-sectional data for telomere length vs age for the DC patients (---) is not significantly different from 0 in any lineage. In contrast, the slope for the cross-sectional results in DC relatives (---) is significantly negative (p<0.001) in all lineages.
Figure 1

Granulocytes

Lymphocytes

Naïve T-Cells

Memory T-Cells

B-Cells

NK Cells

Telomere Length, kb vs. Age, years for different cell types.
Figure 2

A. DC Subtypes vs Relatives

B. Genes

C. Bone Marrow Failure

D. Triad
Figure 3

Granulocytes

Lymphocytes

Naïve T-Cells

Memory T-Cells

B-Cells

NK Cells